(Total Views: 531)
Posted On: 10/27/2021 5:15:01 AM
Post# of 155052
It's not a matter of not being able to fill the trial because COVID-19 isn't going away any time soon. It would only be a matter of how long it would take to fill the trial.
If Cytodyn really wants to assure they hit the endpoints they're going to base the trial size on triple digit p values, p = .009 or less for final trial results. The data from CD12 allows them to figure that out. Why Nader would be overly cautious on hitting significance for severe at interim is because severe on SOC are much more likely to recover then critical. Better for him to be cautious and hit significance at interim then not hit significance and have the whiners out in full force.
If Cytodyn really wants to assure they hit the endpoints they're going to base the trial size on triple digit p values, p = .009 or less for final trial results. The data from CD12 allows them to figure that out. Why Nader would be overly cautious on hitting significance for severe at interim is because severe on SOC are much more likely to recover then critical. Better for him to be cautious and hit significance at interim then not hit significance and have the whiners out in full force.
(15)
(0)
